

Recombinant allergens, 3/18

March 2018—Meridian Life Science introduced its recombinant allergens for the development of serum-based IgE-mediated allergen diagnostic assays. They are capable of binding IgE antibodies in a comparable way to natural allergens and demonstrate good reactivity in in vitro diagnostic tests. The panel is ideally suited to developing quantitative allergy tests that can determine an individual's specific IgE profile.

[Meridian Life Science](#), 901-382-8716